Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX)’s stock price has increased by 20.38 compared to its previous closing price of 1.30. However, the company has seen a 20.38% increase in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-22 that May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences (“Emtora”) has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas (“CPRIT”). This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis (“FAP”) to $20.0 million.
Is It Worth Investing in Biodexa Pharmaceuticals Plc ADR (NASDAQ: BDRX) Right Now?
Additionally, the 36-month beta value for BDRX is 1.28. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The average trading volume of BDRX on May 22, 2025 was 1.55M shares.
BDRX’s Market Performance
BDRX stock saw an increase of 20.38% in the past week, with a monthly gain of 10.21% and a quarterly increase of -57.82%. The volatility ratio for the week is 5.18%, and the volatility levels for the last 30 days are 7.27% for Biodexa Pharmaceuticals Plc ADR (BDRX). The simple moving average for the last 20 days is 13.22% for BDRX stock, with a simple moving average of -70.55% for the last 200 days.
Analysts’ Opinion of BDRX
Many brokerage firms have already submitted their reports for BDRX stocks, with Ladenburg Thalmann repeating the rating for BDRX by listing it as a “Buy.” The predicted price for BDRX in the upcoming period, according to Ladenburg Thalmann is $8 based on the research report published on February 08, 2024 of the previous year 2024.
BDRX Trading at 2.93% from the 50-Day Moving Average
After a stumble in the market that brought BDRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -96.32% of loss for the given period.
Volatility was left at 7.27%, however, over the last 30 days, the volatility rate increased by 5.18%, as shares sank -1.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.94% lower at present.
During the last 5 trading sessions, BDRX rose by +17.69%, which changed the moving average for the period of 200-days by -90.21% in comparison to the 20-day moving average, which settled at $1.3805. In addition, Biodexa Pharmaceuticals Plc ADR saw -61.36% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BDRX
Current profitability levels for the company are sitting at:
- -96.3 for the present operating margin
- -26.12 for the gross margin
The net margin for Biodexa Pharmaceuticals Plc ADR stands at -82.16. The total capital return value is set at -0.82. Equity return is now at value -89.21, with -45.75 for asset returns.
Based on Biodexa Pharmaceuticals Plc ADR (BDRX), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -10.66. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -163.12.
Currently, EBITDA for the company is -7.16 million with net debt to EBITDA at 0.17. When we switch over and look at the enterprise to sales, we see a ratio of -11.33. The receivables turnover for the company is 0.12for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.75.
Conclusion
In conclusion, Biodexa Pharmaceuticals Plc ADR (BDRX) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
